Phase I Program

Note: Other Phase 1 Studies may be open at the Knight, please click here to view

- IRB# 17674: Fusion-NTRK (previously treated) solid tumors
- IRB# 18164: RET Mutations
- IRB# 18788: Tumor Mutation Burden - High
- IRB# 18788: Study of Nivolumab in Combination with Ipilimumab or Nivolumab Monotherapy in Participants with Advanced or Metastatic Solid Tumors of High Tumor Mutational Burden (TMB-H)
- IRB# 16702: A Phase I/IIa Trial With BMS-986158 as Monotherapy or in Combination with Nivolumab in Subjects with Selected Advanced Solid Tumors
- IRB# 16/702: A Study of Oral LOXO-292 in Patients with Advanced Solid Tumors, Including RET-Fusion Non-Small Cell Lung Cancer, Medullary Thyroid Cancer, and Other Tumors with Increased RET Activity
- IRB# 21349: Folate Receptor Alpha Expression - TNBC, NSCLC, EC, OC

- IRB# 21548: Study of Nivolumab in Combination with Ipilimumab in Subjects With Advanced Solid Tumors
- IRB# 21819: A Phase 1-2 Study of ASTX029 in Subjects With Advanced Solid Tumors

- IRB# 16676: BLU-667 in thyroid cancer, non-small cell lung cancer and advanced solid tumors

- IRB# 18164: A Study of Oral LOXO-292 in Patients with Advanced Solid Tumors, Including RET-Fusion Non-Small Cell Lung Cancer, Medullary Thyroid Cancer, and Other Tumors with Increased RET Activity

- IRB# 18788: Study of Nivolumab in Combination with Ipilimumab or Nivolumab Monotherapy in Participants with Advanced or Metastatic Solid Tumors of High Tumor Mutational Burden (TMB-H)

- IRB# 21349: A Study to Evaluate the Safety, Tolerability, and Efficacy of MORAb-202, a Folate Receptor Alpha (FRα)-Targeting Antibody-drug Conjugate (ADC) in Participants With Selected Tumor Types

7/1/2021

http://www.ohsu.edu/research/rda/sol/knight.php
P53 Y220C mutations

No known mutation, phase 1; TREM1 expression phase 2

Locally-advanced or metastatic solid tumor with an NRG1 gene fusion

Solid Tumors likely to express ROR1

Solid Tumor likely responsive to immune checkpoint inhibitors and solid tumors with a KRASG12 mutation

Solid tumors with a BRAF fusion alteration

Solid tumors with a MYC gene mutation

TREM2 expression phase 2

Microsatellite Stable (MSS) colorectal, ovarian, and endometrial

IRB 21998 coming soon

IRB 2223 coming soon

IRB 22580 coming soon

IRB 22680 coming soon

IRB 22798 coming soon

IRB 22902 coming soon

IRB 22986 coming soon

IRB 22863 coming soon

IRB 22925 coming soon

http://www.ohsu.edu/research/rda/so/knight.php